Tibet Cheezheng Tibetan Medicine002287.SZValuation Analysis

As of Oct 19, 2026, Tibet Cheezheng Tibetan Medicine (002287.SZ) trades at a P/E of 16.60x, P/B of 2.16x, P/S of 5.60x, and a dividend yield of 3.26%.
Longitudinal percentile comparison: P/E sits at the 4th percentile over the trailing 10Y window (vs. 4th percentile over 3Y); P/B sits at the 0th percentile over the trailing 10Y window (vs. 1st percentile over 3Y); P/S sits at the 17th percentile over the trailing 10Y window (vs. 54th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 13th percentile within its industry and the 17th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 4.52%, ranking at the 100th percentile over the trailing 20Y window.
The P/E and P/B long-window percentiles differ by only 3.3 points, pointing to a consistent valuation read across both metrics. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Breaking down the total shareholder yield: 3.26% comes from cash dividends, with an implied ~1.25% from buybacks — a fairly balanced mix of both channels. Tibet Cheezheng Tibetan Medicine operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.